pharma · Achondroplasia · Amyloid Cardiomyopathy, Transthyretin-Related · BBOT
BridgeBio Oncology Therapeutics is a pharma organization headquartered in South San Francisco, USA. It trades on NYSE under ticker BBOT. Primary therapeutic focus areas include Achondroplasia, Amyloid Cardiomyopathy, Tra
Phase 2 · small molecule · Achondroplasia
Infigratinib 0.016 mg/kg is a small-molecule fibroblast growth factor receptor (FGFR) inhibitor developed by BridgeBio Oncology Therapeutics for the treatment of achondroplasia, a genetic disorder of bone growth. The compound is formulated under the brand name FEBSELTIQ and operates via inhibition of FGFR signaling, wh
Internal code QBGJ398-201
Infigratinib 0.016 mg/kg is a small-molecule fibroblast growth factor receptor (FGFR) inhibitor developed by BridgeBio Oncology Therapeutics for the treatment of achondroplasia, a genetic disorder of bone growth. The compound is formulated under the brand name FEBSELTIQ and operates via inhibition of FGFR signaling, which is dysregulated in achondroplasia pathogenesis. The program, designated QBGJ398-201, is a Phase 2 trial (NCT04265651) that has been completed as of October 22, 2025. Infigratinib received regulatory approval in the European Union under the marketing authorization holder Helsinn Birex Pharmaceuticals Ltd; however, the EMA application was subsequently withdrawn. The development status reflects a completed Phase 2 program, though the clinical and commercial trajectory remains subject to regulatory and commercial considerations. BridgeBio's strategy centers on addressing an unmet medical need in achondroplasia, a rare genetic disorder affecting skeletal development. Current regulatory status indicates the EU application is no longer active, and approval timelines in other major markets have not been disclosed.
Achondroplasia is the most common form of skeletal dysplasia, affecting approximately 1 in 25,000 live births globally. The condition results from mutations in the FGFR3 gene, leading to constitutive receptor activation and impaired endochondral ossification. Current management is primarily symptomatic and surgical, with no disease-modifying pharmacological therapies approved. The unmet medical need is substantial: patients experience progressive skeletal deformities, short stature, neurological complications including spinal stenosis, and reduced quality of life. Infigratinib represents a targeted approach to modulate the underlying pathophysiology by inhibiting aberrant FGFR signaling.
Market relevance is significant given the rarity of achondroplasia and the absence of approved disease-modifying treatments. The competitive landscape for achondroplasia therapeutics is nascent, with limited approved options. Infigratinib's mechanism—direct FGFR inhibition—aligns with the molecular pathology of the disease. The patient population, while numerically small, represents a high-need cohort with substantial unmet medical need and potential for meaningful clinical benefit. Commercial significance is tempered by the orphan disease status and market size constraints, though regulatory pathways for rare genetic disorders often provide expedited review and market exclusivity incentives. The withdrawal of the EMA application suggests regulatory or commercial challenges that may impact future development strategy.
Drug Class: Fibroblast growth factor receptor (FGFR) inhibitor; classified as an antineoplastic and immunomodulating agent (ATC L01).
Mechanism of Action: Infigratinib inhibits fibroblast growth factor receptor signaling, thereby reducing aberrant FGFR3 activation that drives achondroplasia pathogenesis.
Molecular Type/Modality: Small-molecule inhibitor.
Route of Administration: Not yet disclosed.
Target: Fibroblast growth factor receptor (FGFR).
Related Therapies: Other FGFR inhibitors in development or approved for oncologic indications; achondroplasia-specific therapeutics remain limited.
First Approval: Infigratinib (FEBSELTIQ) received EMA approval under marketing authorization holder Helsinn Birex Pharmaceuticals Ltd; however, the application was subsequently withdrawn. Approval status in other jurisdictions (FDA, PMDA, NMPA) has not been disclosed.
Patent Status: Not yet disclosed.
Also known as: ACH, achondroplastic dwarfism
Prevalence: Prevalence at birth: 1-9 / 100 000 (Worldwide) — source: Orphanet, validated.
Achondroplasia is the most common form of chondrodysplasia, characterized by rhizomelia, exaggerated lumbar lordosis, brachydactyly, and macrocephaly with frontal bossing and midface hypoplasia.
ClinicalTrials.gov lists 46 registered studies for Achondroplasia (AACT aggregate).
Phase breakdown: NA (19), PHASE2 (16), PHASE3 (4), PHASE2/PHASE3 (3), PHASE1 (2), PHASE1/PHASE2 (1), PHASE4 (1)
Common investigational therapies:
Disease data sourced from MONDO Disease Ontology (MONDO:0007037), Orphanet — achondroplasia, NCT00001536, NCT01435629, NCT01516229, NCT01541306, NCT01590446, AACT (ClinicalTrials.gov aggregate), ClinicalTrials.gov, Open Targets Platform (CC BY 4.0).
QBGJ398-201 Phase 2 trial initiated
Phase 2 study (NCT04265651) for infigratinib 0.016 mg/kg in achondroplasia commenced enrollment.
Phase 2 trial completed
QBGJ398-201 Phase 2 study completed as of October 22, 2025; specific results and next steps not yet disclosed.
The competitive landscape for achondroplasia therapeutics is limited, with no directly comparable approved therapies listed in the provided competitor data. The competitor list includes oncologic agents (GLIADEL, TEKINEX, ALUNBRIG, KYPROLIS, EVOLTRA, INLYTA, MEKTOVI, CABAZITAXEL ACCORD, CABOMETYX, CAPECITABINE SANDOZ, UNITUXIN) and a non-steroidal anti-inflammatory (APX-CELECOXIB), none of which are indicated for achondroplasia. These competitors represent approved therapies in oncology and related fields but do not directly compete in the achondroplasia space. Infigratinib's competitive position in achondroplasia is therefore defined by the absence of approved disease-modifying alternatives rather than direct competition with established therapies. The FGFR inhibitor class has established clinical utility in oncology, but application to rare genetic skeletal disorders represents a distinct therapeutic domain. The withdrawal of the EMA application for FEBSELTIQ suggests that regulatory or commercial factors may have influenced the competitive positioning of this program.
| Therapy | Company | Mechanism | Status |
|---|---|---|---|
| GLIADEL | Eisai Co., | Glutathione reductase inhibitor | approved |
| TEKINEX | Teva Pharma GmbH | Protein synthesis inhibitor | approved |
| ALUNBRIG | Lacuna Pharma Pty Ltd | ALK tyrosine kinase receptor inhibitor | approved |
| KYPROLIS | Amgen | 26S proteosome inhibitor | approved |
| EVOLTRA | Amneal Pharma Europe Ltd | DNA polymerase (alpha/delta/epsilon) inhibitor | approved |
| APX-CELECOXIB | Viatris Pharmaceuticals Co., | Cyclooxygenase-2 inhibitor | approved |
| INLYTA | Pfizer Australia Pty Ltd | Vascular endothelial growth factor receptor inhibitor | approved |
| MEKTOVI | Pierre Fabre Australia Pty Ltd | Dual specificity mitogen-activated protein kinase kinase 1 inhibitor | approved |
| CABAZITAXEL ACCORD | Lacuna Pharma Pty Ltd | Tubulin inhibitor | approved |
| CABOMETYX | Ipsen | Hepatocyte growth factor receptor inhibitor | approved |
| CAPECITABINE SANDOZ | Alphapharm Pty Ltd | Thymidylate synthase inhibitor | approved |
| UNITUXIN | United Therapeutics Europe Ltd | Disialoganglioside GD2 binding agent | approved |
| VOSORITIDE | — | Atrial natriuretic peptide receptor B binding agent | Approved |
| INFIGRATINIB | — | Fibroblast growth factor receptor inhibitor | Phase 2 |
Additional associated therapies sourced from Open Targets Platform (CC0), linked to NovaPharmaNews drug profiles where matched.
European Medicines Agency (EMA): Infigratinib (FEBSELTIQ) was approved under marketing authorization holder Helsinn Birex Pharmaceuticals Ltd (EMEA/H/C/005361). The application was subsequently withdrawn; authorization dates and specific withdrawal rationale have not been disclosed.
FDA (United States): Regulatory status in the United States has not been disclosed.
PMDA (Japan): Regulatory status in Japan has not been disclosed.
NMPA (China): Regulatory status in China has not been disclosed.
Infigratinib is being developed for the treatment of achondroplasia, a genetic disorder of bone growth caused by mutations in the FGFR3 gene. It is a fibroblast growth factor receptor inhibitor designed to modulate aberrant FGFR signaling underlying the disease.
Infigratinib (FEBSELTIQ) received European Medicines Agency approval under marketing authorization holder Helsinn Birex Pharmaceuticals Ltd; however, the EMA application was subsequently withdrawn. Approval status in the United States, Japan, and China has not been disclosed.
Infigratinib is a small-molecule fibroblast growth factor receptor (FGFR) inhibitor that blocks aberrant FGFR3 signaling, which is dysregulated in achondroplasia. By inhibiting this pathway, the drug aims to restore normal bone growth and development.
Infigratinib is developed by BridgeBio Oncology Therapeutics. The EMA marketing authorization holder is Helsinn Birex Pharmaceuticals Ltd.
Infigratinib is in Phase 2 development. The QBGJ398-201 Phase 2 trial (NCT04265651) was completed as of October 22, 2025; however, clinical results have not yet been disclosed.
Achondroplasia is the most common form of skeletal dysplasia, affecting approximately 1 in 25,000 live births. It results from mutations in the FGFR3 gene, leading to impaired bone growth, short stature, skeletal deformities, and potential neurological complications.
Infigratinib inhibits fibroblast growth factor receptor (FGFR) signaling, specifically targeting the dysregulated FGFR3 pathway that drives achondroplasia pathogenesis.
Infigratinib is classified as a fibroblast growth factor receptor inhibitor and is categorized as an antineoplastic and immunomodulating agent (ATC L01).
The Phase 2 trial for infigratinib in achondroplasia is NCT04265651, designated QBGJ398-201.
The brand name for infigratinib is FEBSELTIQ.
Achondroplasia currently lacks approved disease-modifying pharmacological therapies. Management is primarily symptomatic and surgical. Infigratinib addresses this unmet need by targeting the underlying FGFR3 dysregulation.
The achondroplasia therapeutics market is nascent with limited approved disease-modifying therapies. No directly competing approved therapies for achondroplasia are listed in current competitive data, though other FGFR inhibitors may be in development.
The route of administration for infigratinib has not yet been disclosed.
The primary endpoints of the QBGJ398-201 Phase 2 trial have not yet been disclosed.
The specific reasons for withdrawal of the FEBSELTIQ EMA application have not been disclosed. Withdrawal may reflect regulatory, efficacy, safety, or commercial considerations.
The target patient population is individuals with achondroplasia, a rare genetic disorder affecting approximately 1 in 25,000 live births globally. Exact enrollment criteria for the Phase 2 trial have not been disclosed.
Infigratinib targets a rare orphan disease with high unmet medical need. Commercial viability is constrained by the small patient population but supported by regulatory incentives for rare disease therapies and the absence of approved alternatives.
Infigratinib 0.016 mg/kg → Drug → Target → Indication → Company → Trials → Competitors
Strategic Implications: BridgeBio's development of infigratinib for achondroplasia represents a targeted approach to a rare genetic disorder with significant unmet medical need. The completion of the Phase 2 trial (QBGJ398-201) marks a critical inflection point; however, the absence of disclosed results and the withdrawal of the EMA application suggest potential regulatory or efficacy challenges. The strategic implications depend on whether Phase 2 data support advancement to Phase 3 or alternative development pathways.
Competitive Implications: The achondroplasia therapeutics market remains nascent, with limited approved disease-modifying therapies. Infigratinib's FGFR inhibitor mechanism is mechanistically sound for achondroplasia but faces competition from other FGFR-targeting approaches in development. The EMA application withdrawal may reflect competitive or regulatory pressures that could influence market access and commercial viability.
Future Catalysts: Key catalysts include disclosure of Phase 2 clinical results, regulatory decisions in major markets (FDA, EMA re-submission if applicable), and advancement to Phase 3 if warranted by efficacy and safety data. The timeline for these catalysts has not been disclosed.
Expected Milestones: Next milestone label and expected timing have not been disclosed. Potential future milestones include Phase 3 initiation, regulatory submissions, or strategic partnership announcements.
Concise, citable answers optimized for AI answer engines.
Intelligence compiled from public regulatory and clinical sources (FDA, EMA, ClinicalTrials.gov and company disclosures). Figures may be editorial or analyst estimates; verify against primary sources before relying on them.